Outlook Therapeutics Inc (OTLK)

[thermo]

Just a general reply: My strong opinion is that management feels they have a very valuable company. But the stock price is reflecting lack of cash and the biotech sector is under lots of pressure right now, so any equity financing hard.

Strategic negotiations drag on so long, so a company like OTLK always has to have a financing plan just based in funds like mine putting money in.

I know this debt financing group. Yes, the debt is expensive (~ 15% - 20% expected return all in) but that should still be cheaper than issuing equity down here (if one is bullish).

So, I think the debt was fine to issue but we'll see more financing near term, in my view.